Policy paper rebukes the push to chemically alter children’s biology.
The European Society of Child and Adolescent Psychiatry (ESCAP) issued a policy statement April 27 advising doctors to not pursue prescribing children treatments that will transgender them.
“ESCAP calls for healthcare providers not to promote experimental and unnecessarily invasive treatments with unproven psycho-social effects and, therefore, to adhere to the “primum-nil-nocere” (first, do no harm) principle,” the policy paper said on page 4.
ESCAP laid out key principles of non-maleficence that they say must be followed when dealing with children who exhibit ‘gender dysphoria’, or a diagnosis given to children before they’re transgendered.
“The principle of non-maleficence: do not use outside the research environment any experimental interventions with potentially irreversible effects, or interventions with unknown long-term consequences,” the policy paper said on page 2.
Notably, ESCAP acknowledges lifelong consequences for children who are transgendered.
According to scientific literature, these consequences can range from sterility, cancer, more cancer, heart problems and death, despite pro-transgender medical institutions claiming otherwise.
The paper also discussed how the decision to transgender a child is based on unreliable data.
“…the poor reliability and instability of a gender dysphoria diagnosis in a specific child over time, but also the possi-ble effects of the decisions to block puberty or preventing medical transitioning on a child’s psychosocial development and mental health,” the policy paper said on page 3.
In a post on X (formerly Twitter) the Society for Evidence-Based Gender Medicine (SEGM) discussed the paper and gave their analysis.
The European Society of Child and Adolescent Psychiatry (ESCAP) published a policy statement on child and adolescent gender dysphoria, calling on healthcare providers to “not to promote experimental and unnecessarily invasive treatments with unproven psycho-social effects and,…
— SEGM (@segm_ebm) April 29, 2024
The Cass Review published in the U.K. has lead some physicians to alter the practice of prescribing transgender drugs to children while other European countries are also scaling back their transgendering operations against children, according to Lifesite.
“Scottish gender clinics and the British National Health Service (NHS) have since halted the prescription of puberty blockers,” Lifesite said. “Other European countries like Denmark and Sweden have also moved away from the so-called ‘affirmative model of care’ of minors who struggle with gender dysphoria in the recent past.”
BREAKING: The Civil War Has Begun— Discover The Globalist Kill List
